New Strategies Targeting Cancer Metabolism: Anticancer Drugs, Synthetic Analogues and Antitumor Agents

New Strategies Targeting Cancer Metabolism: Anticancer Drugs, Synthetic Analogues and Antitumor Agents presents up-to-date synthetic strategies for three categories of antimetabolites: antifolates, purines and pyrimidines, the main classes of antimetabolites which are integrated into various pharmaceutical agents. Many of these antimetabolites are considered potent chemotherapeutic agents which have great potential impact on medical research. These main classes of antimetabolites are used in the treatment of critical diseases including cancer, malignancies, autoimmune diseases, and many other non-malignant diseases. Antineoplastic drugs such as alkylating agents which have significant effects are described. Novel synthetic strategies for many anticancer alkylating agents including nitrogen mustards, chlorambucil, melphalan, ifosamide, oxaliplatin and temozolomide are explored. Natural products have offered some of the most significant drugs for treating cancer, as many drugs currently in clinical use are derived from natural products as camptothecins, vinca alkaloids, and derivatives of podophyllotoxin. They provide a contribution that is essential for modern drug discovery and development. In this book, insights into a broad array of novel compounds are reviewed, well-recognized synthetic approaches are emphasized for further anticancer drug development and discovery, and the biological evaluation of novel synthesized compounds are included. This comprehensive reference is a valuable resource for medical chemists working in drug discovery and development, as well as pharmacologists and biochemists working in related fields.

• Provides the only resource dedicated to synthetic strategies of antimetabolites
• Features synthetic strategies for nucleosides and their analogues
• Includes coverage of purine-, pyrimidine- and antifolate-based anticancer drugs
• The most significant anticancer alkylating agents and natural products are demonstrated

Galal H. Elgemeie is the author of over 270 scientific international papers on heterocyclic chemistry and medicinal chemistry. His research interests include the development and mechanistic understanding of organic reactions and their application to the synthesis of antimetabolic agents. He was an international elected member of the Scientific Board of the International Basic Sciences Programme (IBSP), UNESCO, in Paris, France. He was a postdoctoral fellow of the Alexander von Humboldt Foundation in Germany, the Fulbright in USA, the British Council in England, and then the German Research Foundation (DFG) in Germany. He supervised several cooperation projects with the European Community under the TEMUPS programme, Prof. Elgemeie was nominated as one of the leading scientists of the COMSTECH in the year 2009 Report. Prof. Elgemeie's research activities have received many awards including The African Union Scientific Award "Continental Scientific Award" in Science and Technology, The ISESCO Scientific Award and The Egypt State Honor Award "NILE", among many others.

Reham A. Mohamed-Ezzat is a researcher in the Chemistry of Natural and Microbial Products Department, Pharmaceutical & Drug Industries Research Division, National Research Center in Egypt. She got her B.Sc (2010) in Chemistry & Biochemistry-Faculty of Science. She was awarded her M.Sc. (2015) & PhD degree of science in organic chemistry in 2019 from Helwan University. She has published many books and articles in international journals in the field of bioorganic and medicinal chemistry. She has extensive experience in the field of design and synthesis of novel molecules of medicinal application, as well as the implementation of new strategies in the syntheses of bioactive compounds.